AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01644240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8954
Description: Intravenous infusion
Study NCT01644240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - saline
Description: Intravenous infusion
Study NCT03058627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: FFR guided PCI
Study NCT01390025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCN-032
Description: TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
Study NCT01390025 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 0.9% Sodium Chloride for Injection, USP
Study NCT03690050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode 577 nm subthreshold micropulse laser
Description: On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The DSML surgery will be performed by an Ophthamologist
Study NCT03690050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard threshold laser (532 nm laser)
Description: On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The standard laser surgery will be performed by an Ophthamologist
Study NCT02274883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched Protein Fractions
Description: Enriched protein fractions
Study NCT02274883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Fractions
Description: Protein fractions
Study NCT03379402 — intervention group
Intervention type: OTHER
Intervention: Specimens collection
Description: On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3.
Study NCT03952182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Orthosis (LSO, TLSO)
Description: spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
Study NCT03952182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No orthosis
Description: no orthotic given for spinal fracture. These patient's will be given a bending restriction
Study NCT03982992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab in combination with donor lymphocyte infusion
Description: Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
Study NCT01549717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of a wireless telemetry device
Description: Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
Study NCT02790164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron
Description: Neuromuscular Blockade
Study NCT02790164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal Saline
Study NCT05921565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventional Behavioral Arm
Description: All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
Study NCT02376179 — intervention group
Intervention type: DEVICE
Intervention: Cuffed ETT
Study NCT03917095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Colonic Transendoscopic enteral Tubing.
Description: The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
Study NCT03917095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: The medications were infused into the colon
Study NCT03657641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03657641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT03917095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: The medications were infused into the colon
Study NCT03917095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: The medications were infused into the colon
Study NCT03917095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: The medications were infused into the colon
Study NCT01564147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: immediate therapeutic education
Description: Access to the course of immediate therapeutic education
Study NCT01564147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: therapeutic education delayed
Description: Group receiving therapeutic education 6 months later (control group)
Study NCT00771966 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy
Study NCT00771966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximization of cardiac stroke volume with fluid infusion
Description: Maximization of cardiac stroke volume with fluid infusion
Study NCT03753256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transbond XT
Description: Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants.
Study NCT03753256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protecto®CaF2Nano
Description: Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants.
Study NCT03753256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro Seal®
Description: Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants.
Study NCT03965741 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Follow clinical administration
Study NCT03753256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opal®Seal
Description: Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants.
Study NCT01234025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
Study NCT01234025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
Study NCT01234025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
Study NCT01234025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
Study NCT01234025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
Study NCT00914511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil 200mg
Description: single dose tablet of 200mg avanafil
Study NCT00914511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil 200mg
Description: single tablet dose of 200mg avanafil
Study NCT00190294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIFEPRISTONE 200 mg and misoprostol 400 µg
Description: MIFEPRISTONE 200 mg and misoprostol 400 µg
Study NCT00814502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem CR
Description: After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
Study NCT00814502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
Study NCT03874507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality/Augmented Reality Headset
Description: A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view.
Study NCT04420559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular Injection
Description: Intramuscular Benzathine Penicillin Injection Procedure
Study NCT02161809 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Eating and Physical Activity
Description: The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
Study NCT02161809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Physical Activity
Description: The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
Study NCT03734874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin
Description: 500 mg hesperidin as two capsuls
Study NCT03734874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study NCT00752206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinib
Description: Oral Agent
Study NCT00752206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Agent
Study NCT03465215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital holographic microscopy
Description: Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
Study NCT00859313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab PCA System/15 mcg
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study NCT03496597 — intervention group
Intervention type: PROCEDURE
Intervention: Retinal imaging assessment
Description: * OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus
Study NCT03496597 — intervention group
Intervention type: PROCEDURE
Intervention: blood glucose holter
Description: for 40 subjects, implantation of a blood glucose holter monitor for 7 days
Study NCT02311764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered weekly
Study NCT04830358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuPCV15
Description: 15-valent Pneumococcal conjugate vaccine
Study NCT04830358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: 13-valent Pneumococcal conjugate vaccine
Study NCT03965741 — intervention group
Intervention type: DRUG
Intervention: Apixaban(Eliquis)
Description: Follow clinical administration
Study NCT03965741 — intervention group
Intervention type: DRUG
Intervention: Pradaxa (Dabigatran etexilate)
Description: Follow clinical administration
Study NCT05658588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb
Description: Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
Study NCT01096693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urocortin 2, Urocortin 3
Description: After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3.
Study NCT01096693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Study NCT04340544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
Study NCT04340544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT04013620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept 250 Milligram Intravenous Powder for Solution
Description: Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)
Study NCT02031263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial thermoplasty system
Description: Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
Study NCT02124694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HTUG
Description: HTUG is a group psychotherapy...
Study NCT03157804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)
Study NCT03257839 — intervention group
Intervention type: DEVICE
Intervention: Routine Full-Field Digital Mammography
Description: Routine screening mammography exam, CC + MLO views.
Study NCT03257839 — intervention group
Intervention type: DEVICE
Intervention: Routine Digital Breast Tomosynthesis
Description: Routine screening tomosynthesis exam, CC + MLO views.
Study NCT03257839 — intervention group
Intervention type: DEVICE
Intervention: Automated Whole Breast Ultrasound
Description: Bilateral breast ultrasound performed as an adjunct to mammography.
Study NCT02301117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Study NCT02391363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior treatment
Description: Anxiety management skills with the option to included religious/spiritual beliefs and practices
Study NCT02391363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and referral
Description: Resource counseling and follow-up for mental health and basic needs
Study NCT02312297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg
Study NCT02312297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg
Study NCT00910780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: via oral tablets, everyday
Study NCT00910780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa
Description: via oral tablets, taken once daily
Study NCT00910780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal
Description: via oral tablets, taken once daily
Study NCT04304378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization Techniques (ST)
Description: The Stabilization Techniques intervention provides an opportunity to improve emotion/affect regulation and coping skills. The overarching goal of these sessions is to introduce different ways of managing emotional distress through imagery and stress reduction techniques. ST sessions focus on providing coping mechanisms for managing important symptoms of PTSD (i.e., hyperarousal, negative emotions, and physical symptoms).
Study NCT04304378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilization Techniques with Behavioral Activation (ST+BA)
Description: The Stabilization Techniques with Behavioral Activation intervention includes stabilization techniques as well as sessions targeted at increasing time engaged in physical activities during times outside of the intervention session. Preferred activities are selected by the participant. Strategies to foster engagement in the selected activities will include self-monitoring, structuring and scheduling daily activities, rating the degree of pleasure and accomplishment experienced during engagement in specific daily activities, exploring alternative behaviors related to achieving goals, and using role-play to address specific barriers. Establishing/maintaining routines and behavioral strategies to reduce avoidance and mange negative emotions are emphasized.
Study NCT04304378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
Study NCT04304378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
Study NCT02744885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crave Crush
Description: Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
Study NCT02744885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
Study NCT00748670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixture MicroThread (Micro-Macro)
Description: Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.